SPY330.30+3.33 1.02%
DIA272.81+1.37 0.50%
IXIC10,963.64+184.84 1.71%

CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study In Primary Biliary Cholangitis At The Digital International Liver Congress 2020

Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosis   Self-reported pruritus improved at one year for patients in highest categories of baseline itch Selected

 · 
  • Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosis
     
  • Self-reported pruritus improved at one year for patients in highest categories of baseline itch
  • Selected for inclusion in the "Best of ILC" presentation
    • Results mirror recently reported ENHANCE Phase 3 data confirming anti-cholestatic and anti-pruritic effects of seladelpar